PDCD1 and hepatocellular carcinoma: This study categorized patients with u-HCC into CP class A (CPA) and CP class B (CPB) and assessed the therapeutic efficacy and adverse events (AEs) of combined HAIC, TKI, and PD-1 inhibitor therapy.